Literature DB >> 30025121

Fluorescein Leakage and Optical Coherence Tomography Features of Choroidal Neovascularization Secondary to Pathologic Myopia.

Maurizio Battaglia Parodi1, Pierluigi Iacono2, Francesco Romano1, Francesco Bandello1.   

Abstract

Purpose: We compare the fluorescein angiography (FA) patterns with morphologic alterations detectable on spectral-domain OCT (SD-OCT) in myopic choroidal neovascularization (mCNV) and evaluate whether they influence the effects of intravitreal ranibizumab (IVRI) in an as-needed (PRN) regimen.
Methods: The 49 patients enrolled in this prospective case series underwent a complete ophthalmologic examination, including best-corrected visual acuity (BCVA), FA, and SD-OCT assessment. The main outcome measure was correlation between FA patterns and SD-OCT features. Secondary outcomes were changes in BCVA and central macular thickness (CMT), and characterization of subretinal hyperreflective exudation (SHE).
Results: Three main patterns were identified on the FA: no (5%), minimal (35%), and profuse (59%) leakage CNV. Comparison between minimal versus profuse leakage CNV subtypes revealed no difference regarding baseline and final BCVA, CNV area, choroidal thickness, final CMT, and proportion of intraretinal cysts, subretinal fluid, and external limiting membrane (ELM) interruption; however, the minimal leakage CNV subgroup revealed a lower percentage of SHE (P = 0.0039), required fewer IVRI (P = 0.003), and showed a baseline smaller CMT (P = 0.004). Patients presenting with SHE showed a similar baseline BCVA to those without exudation, but displayed greater final BCVA improvement. CMT was greater at the baseline and the reduction also was more marked. CNV area achieved a significant reduction only in eyes with SHE. ELM interruption was present in all cases compared to 86.3% of eyes without SHE. Lastly, the eyes with SHE required more injections (P = 0.04). Conclusions: Different patterns of mCNV may be identified in FA and they correlate with specific SD-OCT alterations. Moreover, the type of FA leakage may assist in identifying more active mCNV.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30025121     DOI: 10.1167/iovs.17-23640

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  Morphological parameters of myopic choroidal neovascularization as predictive factors of anti-VEGF treatment response.

Authors:  Niccolò Castellino; Maurizio Battaglia Parodi; Andrea Russo; Mario Damiano Toro; Matteo Fallico; Vincenza Bonfiglio; Agatino Davide Maugeri; Teresio Avitabile; Antonio Longo
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

Review 2.  Advances in OCT Imaging in Myopia and Pathologic Myopia.

Authors:  Yong Li; Feihui Zheng; Li Lian Foo; Qiu Ying Wong; Daniel Ting; Quan V Hoang; Rachel Chong; Marcus Ang; Chee Wai Wong
Journal:  Diagnostics (Basel)       Date:  2022-06-08

3.  An Artificial-Intelligence-Based Automated Grading and Lesions Segmentation System for Myopic Maculopathy Based on Color Fundus Photographs.

Authors:  Jia Tang; Mingzhen Yuan; Kaibin Tian; Yuelin Wang; Dongyue Wang; Jingyuan Yang; Zhikun Yang; Xixi He; Yan Luo; Ying Li; Jie Xu; Xirong Li; Dayong Ding; Yanhan Ren; Youxin Chen; Srinivas R Sadda; Weihong Yu
Journal:  Transl Vis Sci Technol       Date:  2022-06-01       Impact factor: 3.048

4.  Algorithm of the major and minor diagnostic criteria for active myopic choroidal neovascularization.

Authors:  Paolo Milani; Marco Mazzola; Mario Cigada; Amedeo Massacesi; Marco Setaccioli; Stefania Moschini; Stefano Ciaccia; Fabrizio Scotti; Elena Mantovani; Davide Soranna; Antonella Zambon; Fulvio Bergamini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-04-18       Impact factor: 3.535

5.  Spectral domain-optical coherence tomography retinal biomarkers in choroidal neovascularization of multifocal choroiditis, myopic choroidal neovascularization, and idiopathic choroidal neovascularization.

Authors:  Rui Gao; Jingxue Ma; Zhengwei Zhang; Qingli Shang; Jialiang Duan
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.